Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionTwo Sigma Investments, Lp
ManagerJohn Overdeck, David Siegel
Latest Disclosed Ownership378,146 shares
Latest Disclosed Value $ 168,857,315
Two Sigma Investments, Lp ownership in VRTX / Vertex Pharmaceuticals Incorporated

On May 15, 2026 - Two Sigma Investments, Lp filed a 13F-HR form disclosing ownership of 378,146 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $168,857,315 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 4,155 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 9,000.99% during the quarter. The current value of the position is $168,966,977 USD.

Two Sigma Investments, Lp has a history of taking positions in derivatives of the underlying security (VRTX) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD and put options representing 1,000 of underlying shares valued at $446,540 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

VRTX / Vertex Pharmaceuticals Incorporated Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 378,146 373,991 9,000.99 168,857 8,867.45 0.1363
2026-02-17 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,155 4,155 1,884 0.0027
2025-08-14 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -4,121 -100.00 0 -100.00
2025-05-15 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,121 -29,039 -87.57 1,998 -85.04 0.0043
2025-02-14 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 33,160 -127,375 -79.34 13,354 -82.12 0.0291
2024-11-14 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 160,535 -171,452 -51.64 74,662 -52.02 0.1636
2024-08-14 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 331,987 7,559 2.33 155,609 14.74 0.3545
2024-05-15 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 324,428 188,254 138.25 135,614 144.76 0.3183
2024-02-14 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 136,174 -123,255 -47.51 55,408 -38.58 0.1273
2023-11-14 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 259,429 -129,454 -33.29 90,214 -34.08 0.2427
2023-08-14 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 388,883 297,628 326.15 136,852 375.99 0.3432
2023-05-15 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 91,255 62,133 213.35 28,752 241.91 0.0822
2023-02-14 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 29,122 29,122 8,410 0.0264
2022-08-15 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -33,644 -100.00 0 -100.00
2022-05-16 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 33,644 33,644 8,780 0.0259
2022-02-14 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -959,684 -100.00 0 -100.00
2021-11-15 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 959,684 959,684 174,077 0.3890
2020-11-16 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -102,102 -100.00 0 -100.00
2020-08-14 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 102,102 -363,044 -78.05 29,641 -73.22 0.1468
2020-05-15 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 465,146 -328,323 -41.38 110,681 -36.29 0.9014
2020-02-14 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 793,469 280,834 54.78 173,730 100.03 0.5226
2019-11-14 2019-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 512,635 95,464 22.88 86,851 13.53 0.2922
2019-08-14 2019-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 417,171 -243,353 -36.84 76,501 -37.04 0.2559
2019-05-15 2019-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 660,524 253,455 62.26 121,503 80.12 0.3939
2019-02-14 2018-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 407,069 -171,514 -29.64 67,455 -39.51 0.2641
2018-11-14 2018-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 578,583 464,469 407.02 111,516 474.97 0.3040
2018-08-14 2018-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 114,114 70,060 159.03 19,395 170.13 0.0578
2018-05-15 2018-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 44,054 -868,670 -95.17 7,180 -94.75 0.0239
2018-02-14 2017-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 912,724 462,416 102.69 136,781 99.78 0.4453
2017-11-14 2017-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 450,308 60,238 15.44 68,465 36.20 0.2427
2017-08-14 2017-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 390,070 -255,360 -39.56 50,268 -28.78 0.1818
2017-05-15 2017-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 645,430 -381,425 -37.14 70,578 -6.70 0.2376
2017-02-14 2016-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,026,855 604,506 143.13 75,648 105.38 0.2901
2016-11-14 2016-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 422,349 422,349 0.00 36,833 0.1335
2016-08-15 2016-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -995,248 -100.00 0 -100.00
2016-05-16 2016-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 995,248 652,347 190.24 79,112 83.35 0.3768
2016-02-16 2015-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 342,901 -87,650 -20.36 43,147 -3.77 0.2069
2015-11-16 2015-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 430,551 274,253 175.47 44,838 132.32 0.2297
2016-02-09 2015-06-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 156,298 156,298 19,300 0.0937
2015-08-14 2015-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 156,298 19,300
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2017-08-14 2017-06-30 13F VERTEX PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2017-05-15 2017-03-31 13F VERTEX PHARMACEUTICALS COM Call 7,900 864 n/a n/a n/a
2016-11-14 2016-09-30 13F VERTEX PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2016-08-15 2016-06-30 13F VERTEX PHARMACEUTICALS COM Call 7,700 662 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-15 2026-03-31 13F VERTEX PHARMACEUTICALS COM Put 1,000 447 n/a n/a n/a
2017-08-14 2017-06-30 13F VERTEX PHARMACEUTICALS COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2017-05-15 2017-03-31 13F VERTEX PHARMACEUTICALS COM Put 17,200 1,881 n/a n/a n/a
2016-11-14 2016-09-30 13F VERTEX PHARMACEUTICALS COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2016-08-15 2016-06-30 13F VERTEX PHARMACEUTICALS COM Put 8,000 688 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.